Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70433 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Takefumi Kishimori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Omi Medical Center, Kusatsu, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Heart Failure, Hypoglycemic Agents. Die Arbeit nennt 31 Literaturangaben.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Aims
Heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes (T2D) commonly coexist and are associated with poor outcomes. Although injectable semaglutide has demonstrated benefits in HFpEF, the effectiveness of oral semaglutide in this setting remains uncertain. This study compared all‐cause death and hospitalisation between oral semaglutide and sitagliptin in patients with HFpEF and T2D. Materials and Methods Using a global healthcare data and analytics platform, the TriNetX research network, we conducted a retrospective multi‐centre observational study. We identified patients aged ≥18 years with HFpEF diagnosed before December 31, 2023 ( N = 1 731 548), of whom 812 259 had concomitant T2D. Among them, 3470 initiated oral semaglutide and 22 840 initiated sitagliptin between October 1, 2019, and December 31, 2023. After propensity score matching, each group included 3452 patients. The primary outcome was all‐cause death; the secondary outcome was hospitalisation.
Results
Over 1 year, the risk for all‐cause death in patients who received oral semaglutide relative to those who received sitagliptin was significantly lower (4.3% [145/3452] vs. 7.0% [229/3452]; log‐rank p < 0.001; hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.50 to 0.75). Similarly, patients who received oral semaglutide experienced fewer hospitalisations than those who received sitagliptin (37.1% vs. 42.4%; log‐rank p < 0.001; HR, 0.83; 95% CI, 0.77 to 0.90).
Conclusions
Oral semaglutide appeared to be associated with a lower 1‐year risk of all‐cause death compared with sitagliptin in patients with HFpEF and T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Omi Medical Center, Kusatsu, Japan.
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Takefumi Kishimori, Takao Kato
Zitieren
APA
Kishimori, T., Kato, T., Iwasaki, Y., Shimada, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., & Okada, M. (2026). Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70433
Vancouver
Kishimori T, Kato T, Iwasaki Y, Shimada T, Wada A, Tani A, et al. Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70433
BibTeX
@article{Kishimori2026,
author = {Kishimori, Takefumi and Kato, Takao and Iwasaki, Yoshihiro and Shimada, Takenobu and Wada, Atsuyuki and Tani, Akira and Yamaji, Ryosuke and Koike, Jumpei and Matsumoto, Takehiro and Yagi, Takafumi and Okada, Masaharu},
title = {Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70433}
}
EUVIMED